Jim Cramer Says Bristol-Myers Squibb Company (BMY)’s ‘Got The One That Everybody Is Buzzing About’
We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...
Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 77% of the company
To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ...
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. closed 6.61% short of its 52-week high of $61.08, which the company reached on November 11th.
5BMY : Bristol-Myers Squibb Options Trading: A Deep Dive into...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025?
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Hennion & Walsh Asset Management Inc. Has $1.34 Million Position in Bristol-Myers Squibb (NYSE:BMY)
Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...
Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
bovnews4d
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.38 which represents a slight increase of $0.47 or 0.84% from the prior close of $55.91. The stock opened at $55.82 and ...